Jennifer R. Wortman
0000-0002-8713-1227
Publication & Citation Trends
Publications
0 total
Mo1809 MICROBIOME AVATAR COLITIS MOUSE MODEL - A TRANSLATIONAL TOOL FOR IN VIVO CHARACTERIZATION OF HETEROGENEITY IN STOOL SAMPLES FROM PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD)
Cited by 0
Semantic Scholar
Su1606: ENGRAFTMENT OF INVESTIGATIONAL MICROBIOME THERAPEUTIC SER-109 IS DURABLE THROUGH 24 WEEKS IN A RANDOMIZED TRIAL (ECOSPOR III) FOR THE TREATMENT OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION
Cited by 0
Semantic Scholar
SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. OA
Cited by 344
Semantic Scholar
110: IMPACT OF SER-109, AN INVESTIGATIONAL MICROBIOME THERAPEUTIC, ON STOOL FATTY ACID METABOLITES IN A PHASE 3 RANDOMIZED TRIAL (ECOSPOR III) FOR TREATMENT OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION (CDI)
Cited by 0
Semantic Scholar
681 SER-301, AN INVESTIGATIONAL, RATIONALLY-DESIGNED BACTERIAL CONSORTIUM FOR MILD-TO-MODERATE ULCERATIVE COLITIS, RECAPITULATES THE EFFECTS OF SER-287, A CONSORTIUM OF FIRMICUTE SPORES, ON REMISSION ASSOCIATED MICROBIAL METABOLITES AND HOST GENE EXPRESSION
Cited by 1
Semantic Scholar
809 RAPID CONVERSION OF PRIMARY TO SECONDARY BILE ACIDS IN SUBJECTS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION (CDI) FOLLOWING SER-109, AN INVESTIGATIONAL MICROBIOME THERAPEUTIC
Cited by 1
Semantic Scholar
35 SER-287, AN INVESTIGATIONAL MICROBIOME THERAPEUTIC, INDUCES IN VIVO AND IN VITRO METABOLOMIC CHANGES ASSOCIATED WITH CLINICAL REMISSION IN PATIENTS WITH ACTIVE MILD-TO-MODERATE ULCERATIVE COLITIS OA
Cited by 0
Semantic Scholar
SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial OA
Cited by 141
Semantic Scholar
Research Topics
Cancer Immunotherapy and Biomarkers
(123)
Immunotherapy and Immune Responses
(105)
Immune cells in cancer
(97)
Gut microbiota and health
(50)
Fungal and yeast genetics research
(47)
Affiliations
Broad Institute
Human Genome Sciences (United States)
University of Maryland, Baltimore
Microsoft (United States)
Center for Infectious Disease Research